Wire · opportunities
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
BioNTech and DualityBio announced topline results from the DYNASTY-Breast02 global Phase 3 trial showing a statistically significant but modest progression-free survival improvement with trastuzumab pamirtecan versus chemotherapy in HR+/HER2-low metastatic breast cancer. Safety concerns include a higher rate of interstitial lung disease, mostly mild but with some severe cases.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
The modest trial benefit and lung toxicity risk redefine patient expectations and clinical use for this breast cancer drug. You should prepare for cautious adoption and highlight safety monitoring if working on HR+/HER2-low metastatic breast cancer therapies.
◆ Coverage
2 sources · 26 Oct 2026
◆ Related on Wire
◆ Topics